Navigation Links
Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
Date:2/7/2008

JENA, Germany, February 7 /PRNewswire/ -- Occlutech GmbH, the leading European manufacturer of coronary occlusion devices today announced that it has obtained approval for its IP position in relation to patents held by AGA Medical Inc. from AIPPI, the European International Association for the Protection of Intellectual Property.

AIPPI is the world's leading non-government organization for research into and protection of intellectual property, and is a respected source for opinions and arbitration on IP matters such as patent interpretation and the use of IP in unfair competition.

In patent infringement litigation filed in Germany by AGA Medical Inc. in 2006, AGA argued and got the courts approval for a broad interpretation of its granted patent claims. During the original grant procedure, however, the Examiners of the European Patent Office did not accept the broad scope of the claims. This created significant reason for Occlutech to appeal the first instance district court's decision that Occlutech literally infringe the AGA patent in Germany and to initiate non-infringement proceedings in several other European countries. Occlutech asked AIPPI for an independent, clarifying opinion which now further supports Occlutech's position.

In a statement Robert Moszner, CEO of Occlutech GmbH said: "We are very pleased with the opinion of AIPPI. In addition to several expert opinions, it strongly supports our view that we are not infringing the patent brought forward by AGA Medical. We have developed a unique technology that is surrounded by its own strong intellectual property and we look forward to having our position confirmed in European and U.S. National courts."

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO) - an undesired channel between the hearts two atria that is present in up to 25% of the population - in a minimally invasive, non-surgical way. The market for PFO occluders in particular is expected to expand significantly as the link between PFO and strokes, as well as severe migraine, becomes increasingly well-documented.

Occlutech develops and manufactures a wide range of occluders that are sold under the Occlutech Figulla brand in over 40 countries in European and international markets. Clinical programs leading to regulatory approval in the US and Japan are also underway.

Contact:

Robert Moszner

e-mail:robert.moszner@occlutech.com

Phone: +49-3641-67-51-20

Susanne Goransson

e-mail: info@occlutech.info

Phone: +46-704336521


'/>"/>
SOURCE Occlutech GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. John Josef Molenda Joins Firms Intellectual Property Practice as Of Counsel
2. StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform
3. Written Statement of Kevin J. OConnor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement
4. Therap Services to Attend 2nd International Conference on Intellectual Disabilities/Mental Retardation as Gold Sponsor
5. Depression can foreshadow intellectual decline in older people
6. Mitchell Medical and Jopari Solutions Team up to Offer eBilling Compliance Services to Automobile Property & Casualty Insurance Carriers to Meet New Minnesota Requirements
7. ZIP codes and property values predict obesity rates
8. New Democracy Corps Battleground Poll of Swing Districts Finds Strong, Bi-Partisan Opposition to Cutting Medicare-Funded Nursing Home Care
9. LearnSomething Names Deborah Faucette to New Position of Senior Vice President of Sales and Marketing
10. Herman Miller, Inc., Announces Strategic Acquisition of Brandrud Furniture, Inc. to Expand Its Product Offerings and Competitive Position in the Healthcare Furnishings Sector
11. Start Licensing, Inc. Further Strengthens Position in Cloning Industry With New Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... Groth Family Insurance, a Washington-based firm offering ... a charity drive to support the family of Cindy Hendrickson, a local mother ... On October 29th of this year, Cindy Hendrickson swerved to avoid an oncoming ...
(Date:12/9/2016)... Ohio (PRWEB) , ... December 09, 2016 , ... ... of miniature, folded, pharmaceutical inserts and outserts. As a means of expanding ... This addition will enable Flottman to individually code professional inserts (PIs) and patient ...
(Date:12/9/2016)... Yorktown Heights, NY (PRWEB) , ... December 09, 2016 , ... ... on Alcoholism and Drug Dependence, Inc. (NCADD) is recommending the film Whispering ... 29 states and the District of Columbia as an education tool in the war ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... An inventor ... amputees to safely ride all types of amusement park rides. , The patent-pending SAFETY ... unit is easy to use and could be set up in a matter of ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Japan , Dec. 9, 2016 Mitsubishi ... ; President & Representative Director, CEO: Dr. Masayuki ... amyotrophic lateral sclerosis (ALS) given edaravone intravenously in 10-14 ... loss as measured by the ALS Functional Rating Scale-Revised ... International Symposium on ALS/MND in Dublin, ...
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 Research ... Vaccines Market 2016-2020" report to their offering. ... The global travel vaccines market ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
(Date:12/9/2016)... Dec. 9, 2016  Forge Therapeutics, Inc. today ... Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance ... the treatment of bacterial infections including those caused ... as an attractive antibacterial target for more than ... suitable chemical starting points has hampered its progress. ...
Breaking Medicine Technology: